Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001106" target="_blank" >RIV/00064190:_____/23:10001106 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10471093

Výsledek na webu

<a href="https://www.resmedjournal.com/action/showPdf?pii=S0954-6111%2823%2900302-5" target="_blank" >https://www.resmedjournal.com/action/showPdf?pii=S0954-6111%2823%2900302-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.rmed.2023.107414" target="_blank" >10.1016/j.rmed.2023.107414</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient

Popis výsledku v původním jazyce

The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research. (C) 2023 The Authors

Název v anglickém jazyce

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient

Popis výsledku anglicky

The development of monoclonal antibody therapies targeting specific components of the pathways relevant to asthma pathophysiology has revolutionized treatment of severe asthma both in adults and children and helped to further unravel the heterogeneity of this disease. However, the availability of multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance for specialists undertaking care of patients with severe asthma. In this review, we provide an overview of the data supporting the clinical efficacy of biologics in distinct asthma phenotypes/endotypes. We also focus on the role of biomarkers and treatable traits, including comorbidities, in the choice of asthma biologics, highlight which treatments have been demonstrated to be steroid sparing in corticosteroid dependent asthma, and provide practical guidance that can drive shared decision making on treatment choice with patients. In addition, we summarize what is known to date regarding long-term safety of these drugs, and lastly, discuss future directions in biologics research. (C) 2023 The Authors

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

RESPIRATORY MEDICINE

ISSN

0954-6111

e-ISSN

1532-3064

Svazek periodika

218

Číslo periodika v rámci svazku

218

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

001091782100001

EID výsledku v databázi Scopus

2-s2.0-85173285834